Eli Lilly invests in startup Abridge for clinical trial recruitment
Eli Lilly has invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach into the life sciences. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…
Eli Lilly has invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach into the life sciences.
The investment, made through Lilly’s venture arm, is meant to help ...
Source: Endpoints News